author-photo

Loredana Elia

Sapienza University of Rome

100

Papers

2456

Citations

Citation Trend

Filter By

Papers (71) Sort By

Journal Conference Others

Donor cell derived mantle cell lymphoma in a HSCT sibling donor-recipient pair: intrinsic biological clock in lymphomagenesis.

2021 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (0)
MYB rearrangements and over-expression in T-cell acute lymphoblastic leukemia.

2021 Genes, Chromosomes and Cancer
Show All
- Source
- Cite
- Save
Citations (3)
Author response for "Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia‐positive acute lymphoblastic leukaemia"

2021
Show All
- Source
- Cite
- Save
Citations (0)
Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage Acute Lymphoblastic Leukemia patients treated in GIMEMA clinical trials since 1996.

2021 American Journal of Hematology
Show All
- Source
- Cite
- Save
Citations (0)
Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 (Leukemia, (2019), 33, 8, (1910-1922), 10.1038/s41375-019-0413-0)

2020 Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.

2020 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (59)
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913.

2020 Haematologica
Show All
- Source
- Cite
- Save
Citations (15)
APPLICABILITY OF DROPLET DIGITAL PCR (DDPCR) FOR MINIMAL RESIDUAL DISEASE MONITORING (MRD) IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: PS935

2019
Show All
- Source
- Cite
- Save
Citations (0)
Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

2019 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial

2019 Blood
Show All
- Source
- Cite
- Save
Citations (22)